Browsing by Author "YAVUZ PEHLIVAN"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    A real-life analysis of patients with rheumatologic\rdiseases on biological treatments: Data from TURKBIO\rRegistry
    (2022) gercek can; Fatos Onen; Dilek Solmaz; YAVUZ PEHLIVAN; Cemal Bes; Sema Yilmaz; Merih Birlik; Sedat Çapar; SONER ŞENEL; Suleyman Serdar Koca; mehmet akif öztürk; Özgül Soysal Gündüz; Ayse Cefle; Servet Akar; Ismail Sari; Ayten Yazici; ABDURRAHMAN TUFAN; SEMINUR HAZNEDAROGLU; Gozde Yildirim-Cetin; Servet Yolbas; Berna Goker; Ediz Dalkılıç; Nurullah Akkoç; Şükran Erten; Nevsun Inanc; Haner Direskeneli; Niels Steen Krogh; Sule Yavuz; Fatih Yıldız; Neslihan Yilmaz
    Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey.\rThis study aimed to provide an overview of TURKBIO data collected by June 2018.\rMethods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis\r(AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and\rclinical features, disease activity markers, and other follow-up parameters, current and previous treatments,\rand adverse events were registered electronically at each visit using open-source software. The\rregistration of patient-reported outcome measures was carried out electronically by the patients using\rtouch screens.\rResults: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588\rpatients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number\rof patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of\rpatients and also visits steadily increased by years. The yearly mean number of visits per patient was\rfound to be 2.3. Significant improvements in disease activity and health assessment parameters were\robserved following the biological treatments. Biologics were often given in combination with a conventional\rsynthetic disease-modifying antirheumatic drug in patients with RA. Infections were the\rmost commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12\rpatients, malignancy in 18, and treatment-related mortality in 31.\rConclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic\rdiseases in Turkey.
  • No Thumbnail Available
    Item
    Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry
    (2023) AHMET KARATAŞ; Rabia Pişkin Sağır; Suleyman Serdar Koca; Ediz Dalkılıç; gercek can; YAVUZ PEHLIVAN; Ayten Yazici; Nevsun Inanc; Ayse Cefle; Zeynep Ertürk; Servet Akar; ABDURRAHMAN SONER SENEL; Merih Birlik; Nurullah Akkoç; Fatos Onen
    Background/aim: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the antirheumatic agents in inflammatory diseases. The aim of the study was to determine whether the body mass index (BMI) is involved in the response to rituximab in rheumatoid arthritis (RA). Materials and methods: This multicenter retrospective study included 206 RA patients who received rituximab from the Turkish Biologic (TURKBIO) registry between 2011 and the end of May 2017. Demographic and clinical data including age, sex, disease type, disease duration, and previous or current treatment with disease-modifying antirheumatic drugs (DMARDs) and biological drug durations are stored in the database. Patients with a BMI ≥30 kg/m2 were classified as obese, and patients with a BMI <30 kg/m2 were classified as nonobese. Kaplan-Meier survival analysis was performed to estimate the drug survival. The subgroups were compared using the log-rank test. Results: The mean BMI of 206 patients included in the study was 27.05 (17.2–43.4) kg/m2. There were 59 (28.6%) patients in the obese group and 147 (71.4%) patients in the nonobese group. The mean age, female percentage, and baseline disease activity score 28 (DAS28) were higher in the obese group than in the nonobese group. However, the ΔDAS28 at both 6 and 12 months were not significantly different between the groups (p = 0.785 and p = 0.512, respectively). Patient pain Visual Analogue Scale (VAS), patient fatigue VAS, and patient global VAS scores were also significantly higher at baseline in the obese group (p = 0.003, p = 0.006, and p = 0.006, respectively). However, no significant difference was found in terms of changes in patient pain VAS, patient fatigue VAS, patient global VAS and physician global VAS scores at 6 and 12 months compared to those at baseline. Rituximab treatment was ongoing for 71.2% of the obese and 63.3% of the nonobese patients (p = 0.279). The median drug survival duration was 77 months in the obese group and 62 months in the nonobese group (p = 0.053). The estimated drug survival rates for rituximab were not statistically significantly different in the obese and nonobese groups. Rituximab-related side effects were also similar between the groups. Conclusion: In obese and nonobese patients with RA, rituximab treatment exhibits similar side effects and similar long-term efficacy. These results suggest that obesity does not alter drug survival for rituximab and response rates, in RA and rituximab may be a favorable treatment agent in patients with RA and obesity.